NxStage

Last updated
NxStage Medical, Inc.
Type Subsidiary
Industry Medical devices
FoundedDecember 1998;24 years ago (1998-12)
FounderC. David Finch, Jr., MD and Jeffrey H. Burbank
Headquarters,
U.S.
ProductsSystem One
RevenueIncrease2.svg $393 million (2017)
Increase2.svg -$14 million (2017)
Total assets Increase2.svg $325 million (2017)
Total equity Increase2.svg $213 million (2017)
Number of employees
3,800 (2017)
Parent Fresenius Medical Care
Website www.nxstage.com
Footnotes /references
[1]

NxStage Medical, Inc. Is an American company that develops, manufactures, and markets systems for the treatment of chronic kidney disease, acute kidney injury, and hypervolemia. It is a subsidiary of Fresenius Medical Care. System One, a portable hemodialysis system, is the company's primary product. [1]

Contents

History

The company was founded by C. David Finch, Jr., MD [2] and Jeffrey H. Burbank in December 1998. [3]

In 2003, the company launched System One in the critical care market. It received Food and Drug Administration clearance for home hemodialysis in June 2005. [4]

In October 2005, the company became a public company via an initial public offering. [5]

On November 2, 2005, the company received the Nixon Peabody/Smith&Nephew Medical Device Innovation Award in the Start-Up category from the Massachusetts Medical Device Industry Council (MassMEDIC). [6]

In December 2014, the company received Food and Drug Administration clearance for System One to be used overnight while patients are sleeping. [7]

In August 2017, the company received Food and Drug Administration clearance for System One for solo home hemodialysis, without a care partner, during waking hours. [8]

In February 2019, the company was acquired by Fresenius Medical Care. [9] [10]

Related Research Articles

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

<span class="mw-page-title-main">Medtronic</span> Irish tax-registered medical device company

Medtronic plc is an American medical device company. The company's operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Ireland due to its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies.

<span class="mw-page-title-main">Conivaptan</span> Chemical compound

Conivaptan, sold under the brand name Vaprisol, is a non-peptide inhibitor of the receptor for anti-diuretic hormone, also called vasopressin. It was approved in 2004 for hyponatremia. The compound was discovered by Astellas and marked in 2006. The drug is now marketed by Cumberland Pharmaceuticals, Inc.

Fresenius SE & Co. KGaA is a European multinational health care company based in Bad Homburg vor der Höhe, Germany. It provides products and services for dialysis in hospitals, as well as inpatient and outpatient medical care. The company is involved in hospital management and in engineering and services for medical centers and other health care facilities.

<span class="mw-page-title-main">Home hemodialysis</span>

Home hemodialysis (HHD) is the provision of hemodialysis to purify the blood of a person whose kidneys are not working normally, in their own home. One advantage to doing dialysis at home is that it can be done more frequently and slowly, which reduces the "washed out" feeling and other symptoms caused by rapid ultrafiltration, and it can often be done at night, while the person is sleeping.

Artificial kidney is often a synonym for hemodialysis, but may also refer to the other renal replacement therapies that are in use and/or in development. This article deals mainly with bioengineered kidneys/bioartificial kidneys that are grown from renal cell lines/renal tissue.

Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives.

<span class="mw-page-title-main">Hospira</span>

Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.

Hemoperfusion or hæmoperfusion is a method of filtering the blood extracorporeally to remove a toxin. As with other extracorporeal methods, such as hemodialysis (HD), hemofiltration (HF), and hemodiafiltration (HDF), the blood travels from the patient into a machine, gets filtered, and then travels back into the patient, typically by venovenous access.

ICU Medical, Inc. is a San Clemente, California-based company with global operations. ICU Medical products are designed to prevent bloodstream infections and protect healthcare workers from exposure to infectious diseases or hazardous drugs. ICU Medical product line includes intravenous therapy (IV) products, pumps, needle-free vascular access devices, custom infusion sets, closed system hazardous drug handling devices and systems, sensor catheters, needle-free closed blood sampling systems, and hemodynamic monitoring systems.

<span class="mw-page-title-main">United Therapeutics</span> American biotech company based in Maryland

United Therapeutics Corporation is an American publicly traded biotechnology company and public benefit corporation listed on the NASDAQ under the symbol UTHR. It develops novel, life-extending technologies for patients in the areas of lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.

<span class="mw-page-title-main">Apixaban</span> Anticoagulant medication

Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. Specifically, it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. It is used as an alternative to warfarin and does not require monitoring by blood tests or dietary restrictions. It is taken by mouth.

Peginesatide, developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin.

<span class="mw-page-title-main">Zynex</span> Medical device manufacturer

Zynex, Inc. is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis and cardiac monitoring. Thomas Sandgaard founded Zynex Medical in 1996.

<span class="mw-page-title-main">Rockwell Medical</span>

Rockwell Medical Inc. is a company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).

<span class="mw-page-title-main">Difelikefalin</span> Chemical compound

Difelikefalin, sold under the brand name Korsuva, is an analgesic opioid peptide used for the treatment of moderate to severe itching. It acts as a peripherally specific, highly selective agonist of the κ-opioid receptor (KOR).

<span class="mw-page-title-main">Patiromer</span> Drug used for the treatment of hyperkalemia

Patiromer, sold under the brand name Veltassa, is a medication used to treat high blood potassium. It is taken by mouth. It works by binding potassium in the gut.

CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Sanifit Therapeutics.

Diaverum is a Swedish multinational healthcare organisation that provides life-enhancing renal care to patients with chronic kidney disease. The company has over 440 clinics in 23 countries, Europe, Latin America, the Middle East and Asia.

<span class="mw-page-title-main">Serdexmethylphenidate</span> CNS Stimulant (prodrug)

Serdexmethylphenidate is a prodrug of dexmethylphenidate created by the pharmaceutical company KemPharm. The compound was first approved by the FDA as one of the active ingredients in Azstarys for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents, and adults in March 2021. Serdexmethylphenidate is a prodrug which has a delayed onset of action and a prolonged duration of effects compared to dexmethylphenidate, its parent compound.

References

  1. 1 2 "NxStage Medical, Inc. 2017 Form 10-K Annual Report". U.S. Securities and Exchange Commission.
  2. Who, Marquis Who's (2014-01-10). "C. David Finch Jr. MD". Elite American Physicians. Retrieved 2019-10-24.
  3. "Company Overview of NxStage Kidney Care, Inc". Bloomberg L.P. 15 July 2023.
  4. "NxStage Medical Receives FDA Clearance for Home Hemodialysis System" (Press release). Business Wire. June 29, 2005.
  5. "NxStage Medical rolls out lower-priced IPO". American City Business Journals . October 24, 2005.
  6. "MassMEDIC Honors NxStage Medical with Innovation Award for Portable Home Hemodialysis System" (Press release). Business Wire. November 2, 2005.
  7. Seiffert, Don (December 29, 2014). "NxStage nabs first-ever FDA approval for overnight home hemodialysis". American City Business Journals .
  8. "NxStage Medical Announces FDA Clearance for Solo Home Hemodialysis Using NxStage® System One™" (Press release). PR Newswire. August 28, 2017.
  9. BANNOW, TARA (February 26, 2019). "Fresenius Medical Care closes $2 billion NxStage acquisition". Modern Healthcare .
  10. "Fresenius Medical Care completes acquisition of NxStage Medical" (Press release). PR Newswire. February 26, 2019.